You are here

Comprehensive Evaluation of Cell Therapy for NICM

A new STEM CELLS Translational Medicine article from researchers led by Roberto Bolli (University of Louisville, Louisville, KY, USA) provides a comprehensive evaluation of the efficacy and safety of cell therapy for non-ischemic dilated cardiomyopathy (NICM). Tripathi et al. report that their meta-analysis provides evidence for safety and a degree of efficacy – no major adverse cardiac events were reported and while improved left ventricular systolic function, left ventricular diastolic dimensions, and functional capacity in patients with NICM were observed. Overall, these results support the concept that cell therapy remains a promising therapeutic option for NICM.